Compare Huntington Bancshares Incorporated (HBAN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Repligen Corporation Common Stock — how do they compare? Huntington Bancshares Incorporated trades at $15.19 (market cap $30.79B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Huntington Bancshares Incorporated is far larger — about 2.7× Repligen Corporation Common Stock's market cap, and Huntington Bancshares Incorporated pays a 4.07% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Repligen Corporation Common Stock for 0 Days on average.
| HBAN | RGEN | |
|---|---|---|
Market Cap | $30.79B | $11.31B |
Volume | 16,522,211 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $19.27 | $194.57 |
52-Week Low | $15.02 | $102.87 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | $49.31B | $11.20B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.24, down 1.04% today, with a bearish technical signal and mixed earnings history. The stock shows stable profitability with a 24.77% net income margin and a P/E of 11.72, below industry averages. Recent news highlights pressure from higher interest rates, with the company cutting its 2027 earnings outlook amid margin compression and slower loan growth.
The outlook is cautious due to interest rate headwinds and revised guidance, but analyst consensus remains positive with a $19.60 price target. Risks include competitive pressures and economic sensitivity, while shareholder returns via dividends and buybacks provide support. Upside depends on execution amid a challenging rate environment.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
